According to the study’s abstract in The Lancet, TAVR with Acurate neo2 failed to meet non-inferiority. It also resulted in ...

Medtronic has announced the Small Annuli ... trial’s two-year outcomes of the Evolut transfemoral transcatheter aortic valve ...

The study found that early intervention led to an 80% reduction in heart failure hospitalisations one year after treatment.

Medtronic this week announced it received CE Mark approval for an expanded indication of its Evolut Pro+ and Evolut FX TAVI ...

Recent FDA updates in the areas of cardiac intervention, hypertension and arrhythmia disorders expand the pool of available ...

The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR ... But change may be afoot. Medtronic recently released two-year ...

Medtronic has teamed up with Star Jones to get women talking about heart health. The TV personality is lending her star power ...

Frye Regional Medical Center, a Duke LifePoint facility and Duke Health affiliate in Heart in Hickory, has successfully ...

The good news is there is a less invasive technique called transcatheter aortic valve replacement (TAVR) that benefits patients without a long recovery time and hospital stay. TAVR gets you back ...

On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system. In the trial, TAVR, which assists patients ...

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis early in the disease process while patients still had no symptoms or other ...